Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Hisse Senetlerindeki Sıralama
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Hisse Fiyatı
$4.48
Piyasa Değeri
$4.99B
Değişim (1 gün)
-5.20%
Değişim (1 yıl)
-41.89%
Ülke
CN
Ticaret Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategori
Healthcare
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) için P/B oranı
October 2026 itibarıyla P/B oranı TTM: 3.88
Shenzhen Salubris Pharmaceuticals Co., Ltd. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 3.88'dir. 2024 yılının sonunda şirketin P/B oranı 3.96 idi.
Shenzhen Salubris Pharmaceuticals Co., Ltd. için P/B oranı geçmişi 2006 - 2026 arası
Her yılın sonunda P/B oranı
| Yıl | P/B Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 3.88 | -37.25% |
| 2025 | 6.18 | 56.35% |
| 2024 | 3.96 | -12.84% |
| 2023 | 4.54 | -0.14% |
| 2022 | 4.54 | 25.18% |
| 2021 | 3.63 | -31.38% |
| 2020 | 5.29 | 65.13% |
| 2019 | 3.20 | 5.19% |
| 2018 | 3.05 | -57.11% |
| 2017 | 7.10 | 24.43% |
| 2016 | 5.71 | -16.88% |
| 2015 | 6.86 | 12.33% |
| 2014 | 6.11 | -14.97% |
| 2013 | 7.19 | 11.94% |
| 2012 | 6.42 | 55.67% |
| 2011 | 4.12 | -53.03% |
| 2010 | 8.78 | 74.01% |
| 2009 | 5.05 | -76.40% |
| 2008 | 21.39 | -44.68% |
| 2007 | 38.66 | -13.03% |
| 2006 | 44.45 | 0.00% |
Benzer şirketler veya rakipler için P/B oranı
| Şirket | P/B Oranı | P/B Oranı Farkı | Ülke |
|---|---|---|---|
| 9.3984 | 142.36% |
US
|
|
| 2.0545 | -47.02% |
FR
|
|
| 8.6921 | 124.14% |
JP
|
|
| 2.1872 | -43.60% |
US
|
|
| 1.5197 | -60.81% |
CH
|
